Rubin C M, Larson R A, Anastasi J, Winter J N, Thangavelu M, Vardiman J W, Rowley J D, Le Beau M M
Department of Pediatrics, University of Chicago, IL.
Blood. 1990 Dec 15;76(12):2594-8.
We have identified an identical reciprocal translocation between the long arms of chromosomes 3 and 21 with breakpoints at bands 3q26 and 21q22, [t(3;21)(q26;q22)], in the malignant cells from five adult patients with therapy-related myelodysplastic syndrome (t-MDS) or acute myeloid leukemia (t-AML). Primary diagnoses were Hodgkin's disease in two patients and ovarian carcinoma, breast cancer, and polycythemia vera in one patient each. Patients had been treated with chemotherapy including an alkylating agent for their primary disease 1 to 18 years before the development of t-MDS or t-AML. We have not observed the t(3;21) in over 1,500 patients with a myelodysplastic syndrome or acute myeloid leukemia arising de novo or in over 1,000 patients with lymphoid malignancies. We have previously reported that the t(3;21) occurs in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Thus, the t(3;21) appears to be limited to t-MDS/t-AML and CML, both of which represent malignant disorders of an early hematopoietic precursor cell. These results provide a new focus for the study of therapy-related leukemia at the molecular level.
我们在5例患有治疗相关骨髓增生异常综合征(t-MDS)或急性髓系白血病(t-AML)的成年患者的恶性细胞中,发现了3号和21号染色体长臂之间相同的相互易位,断点位于3q26和21q22带,[t(3;21)(q26;q22)]。其中2例患者的原发诊断为霍奇金淋巴瘤,另3例患者的原发诊断分别为卵巢癌、乳腺癌和真性红细胞增多症。这些患者在发生t-MDS或t-AML的1至18年前,曾因原发性疾病接受过包括烷化剂在内的化疗。在1500多例原发性骨髓增生异常综合征或急性髓系白血病患者以及1000多例淋巴系统恶性肿瘤患者中,我们均未观察到t(3;21)。我们之前曾报道t(3;21)出现在费城染色体阳性的慢性髓性白血病(CML)中。因此,t(3;21)似乎仅限于t-MDS/t-AML和CML,这两种疾病均代表早期造血前体细胞的恶性疾病。这些结果为在分子水平上研究治疗相关白血病提供了新的重点。